Annals of Surgical Oncology

, Volume 25, Issue 3, pp 660–666 | Cite as

Core Body Temperature but Not Intraabdominal Pressure Predicts Postoperative Complications Following Closed-System Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Administration

  • M. Goldenshluger
  • D. Zippel
  • A. Ben-Yaacov
  • J. Dux
  • T. Yalon
  • A. Zendel
  • S. Rayman
  • E. Mor
  • H. Berkenstadt
  • H. Fogel-Grinvald
  • M. Ventorrero
  • A. Nissan
Gastrointestinal Oncology



Hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS), performed using closed-abdomen technique (CAT), may affect intraabdominal pressure (IAP). High IAP may increase postoperative complications due to decreased venous return and hypoperfusion to vital organs. Elevated core body temperature (CBT) may cause multiorgan dysfunction. Low IAP or CBT could result in suboptimal HIPEC and potentially translate into early disease recurrence. The aim of the present study is to identify possible correlations between IAP or CBT and postoperative complications.

Patients and Methods

Continuous intraabdominal pressure measurement was performed by intraabdominal catheter. Inflow temperature was set at 44 °C, and mean perfusate temperature was 42 °C. CBT was measured continuously in the distal esophagus. We compared the rate of postoperative complications between the low IAP group (2–10 mmHg, n = 28), target IAP group (10–20 mmHg, n = 71), and high IAP group (20–34 mmHg, n = 16) as well as with CBT as a continuous variable.


115 patients were included in the study. There was no difference between IAP groups in terms of age, gender, primary diagnosis, operative peritoneal cancer index, CBT, or operative time. There was no correlation between IAP and postoperative complications or with prolonged hospital stay. On multivariate analysis, elevated mean CBT was a positive predictor of postoperative complications (p = 0.035).


IAP level during closed-abdomen technique HIPEC is not associated with postoperative complications. However, elevated CBT may increase postoperative complications.



The authors have no commercial disclosures relevant to this work.


  1. 1.
    Maciver AH, Al-Sukhni E, Esquivel J, Skitzki JJ, Kane JM, Francescutti VA. Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS/HIPEC) and perioperative practices: an international survey of high-volume surgeons. Ann Surg Oncol. 2016;
  2. 2.
    Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016;7(1):18–28. Scholar
  3. 3.
    Kanakoudis AF, Petrou A, Michaloudis D, Chortaria GKA. Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Anaesthesia. 1996;51:1033–36.CrossRefPubMedGoogle Scholar
  4. 4.
    Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, Chauffert, et al. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol. 2010;17(7):1957–63. Scholar
  5. 5.
    Elias D, Franc G, Boutitie F, Quenet F, Bereder JM, Baudouin M, Lorimier G. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. 2016;28(1):63–68.
  6. 6.
    Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1(5):0–1.Google Scholar
  7. 7.
    Dahl O. Status of clinical hyperthermia. Acta Oncol. 1999; 38: 863–73. CrossRefPubMedGoogle Scholar
  8. 8.
    Kajdi M, Beck-schimmer B, Held U, Kofmehl R, Lehmann K, Ganter MT. Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience. World J Surg Oncol. 2014;12(1):1–9. Scholar
  9. 9.
    Bouchama A, Knochel JP. Heat stroke. N Engl J Med. 2002;346(25):1978–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Malbrain MLNG, Cheatham ML, Kirkpatrick A, Sugrue M, Parr M, Waele JD, Balogh H, et al. Results from the International Conference of experts on intra-ABDOMINAL hypertension and abdominal compartment syndrome. I. definitions. Intensive Care Med. 2006;32(11):1722–32. Scholar
  11. 11.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240(2):205–213. Scholar
  13. 13.
    Ceelen WP, Flessner MF, et al. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7(2):108–15. Scholar
  14. 14.
    Kusamura S et al. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;15;98(4):247–52CrossRefPubMedGoogle Scholar
  15. 15.
    Schaaf L, Kuip H, Zopf W, Winter S, Munch M, Murdter T, Thon KP, et al. A temperature of 40 °C appears to be a critical threshold for potentiating cytotoxic chemotherapy in vitro and in peritoneal carcinomatosis patients undergoing HIPEC. Ann Surg Oncol. 2015:758–65.
  16. 16.
    Sessler DI. Perioperative thermoregulation and heat balance. Lancet. 2017;387(10038):2655–64. Scholar
  17. 17.
    Pelz JOW, Doerfer J, Decker M, Dimmler A, Hohenberger W, Meyer T. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis. 2007:22:941–47. Scholar
  18. 18.
    Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;20:8.
  19. 19.
    Samel S, Singal A, Becker H, Post S, Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol. 2000; 26: 222–26. Scholar
  20. 20.
    Westermann AM, Wiedemann GJ, Jager E, Jager D, Katschinski DM, Knuth A, Vörde sive Vörding PZ. A Systemic Hyperthermia Oncologic Working Group trial. Oncology. 2003;53792:312–21. Scholar
  21. 21.
    Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244(1):106–112. Scholar
  22. 22.
    Facy O, Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin. Ann Surg. 2012;0(0):1. Scholar
  23. 23.
    Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 2008;15(1):339–44. Scholar
  24. 24.
    Malbrain MLNG. Different techniques to measure intra-abdominal pressure (IAP): time for a critical re-appraisal. Appl Physiol Intensive Care Med 2 Physiol Rev Ed. 2012:13–27.
  25. 25.
    Chopra SS, Wolf S, Rohde V, Freimann FB. Pressure measurement techniques for abdominal hypertension: conclusions from an experimental model. Crit Care Res Pract. 2015; Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  1. 1.Department of General and Oncological-Surgery (Surgery C), Chaim Sheba Medical Center - Affiliated to the Sackler Faculty of MedicineTel Aviv UniversityTel HashomerIsrael
  2. 2.Department of Anesthesiology, Affiliated to the Sackler Faculty of MedicineTel Aviv UniversityTel HashomerIsrael
  3. 3.The Faculty of Medicine, School of Occupational TherapyHebrew UniversityJerusalemIsrael

Personalised recommendations